Open access
Open access
Powered by Google Translator Translator

Covid-19

Perspective: The concept of classical herd immunity may not apply to COVID-19.

13 Apr, 2022 | 10:54h | UTC

The Concept of Classical Herd Immunity May Not Apply to COVID-19 – The Journal of Infectious Diseases

News Release: NIH experts discuss controlling COVID-19 in commentary on herd immunity – NIH News Releases

 

Commentary on Twitter

 

Cohort Study: Risk of adverse events after covid-19 in Danish children and adolescents and effectiveness of the Pfizer vaccine in adolescents.

12 Apr, 2022 | 10:07h | UTC

Risk of adverse events after covid-19 in Danish children and adolescents and effectiveness of BNT162b2 in adolescents: cohort study – The BMJ

 

AHA Scientific Statement: SARS-CoV-2 infection and associated cardiovascular manifestations and complications in children and young adults.

12 Apr, 2022 | 09:59h | UTC

SARS-CoV-2 Infection and Associated Cardiovascular Manifestations and Complications in Children and Young Adults: A Scientific Statement From the American Heart Association – Circulation

News Release: Heart issues after COVID-19 uncommon in children and young adults, more research needed – American Heart Association

Commentary: COVID-19 CV Complications in Children Are Rare, Treatable: AHA Statement – TCTMD

 

Cohort Study: Predictors of severe illness in children with multisystem inflammatory syndrome after SARS-CoV-2 infection.

12 Apr, 2022 | 09:57h | UTC

Predictors of severe illness in children with multisystem inflammatory syndrome after SARS-CoV-2 infection: a multicentre cohort study – Canadian Medical Association Journal

News Release: Children older than 5 at higher risk of COVID-19-related multisystem inflammatory syndrome – Canadian Medical Association Journal

Commentary: Older Kids More Vulnerable to MIS-C: Study – HealthDay

 

More data suggests the Omicron variant causes milder disease compared to the Delta variant.

12 Apr, 2022 | 09:49h | UTC

Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study – The Lancet

Commentary: Covid-19: Symptomatic infection with omicron variant is milder and shorter than with delta, study reports – The BMJ

Related:

Another study suggests a lower risk of hospitalization and death from infection with SARS-CoV-2 Omicron variant vs. Delta.

Perspective: Challenges in inferring intrinsic severity of the SARS-CoV-2 Omicron variant.

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa.

Cohort Study: Incidence rates and clinical outcomes of SARS-CoV-2 infection with the Omicron and Delta variants in children younger than 5 years in the US.

[Preprint] SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters.

[Preprint] Study showed reduced clinical severity of Covid-19 patients admitted to hospitals in Gauteng, South Africa, during the Omicron-dominant fourth wave – “any combination of a less-virulent virus, comorbidities, high immunity from prior infection(s) or vaccination may be important contributors to this clinical presentation”.

Early data from South Africa hints Omicron variant may cause less severe Covid, but more research is needed.

Too early to tell, but preliminary information from doctors in South Africa suggests the new Covid variant Omicron may be associated with less severe disease.

 

COVID-19 disease severity in children infected with the Omicron variant.

12 Apr, 2022 | 09:47h | UTC

COVID-19 Disease Severity in Children Infected with the Omicron Variant – Clinical Infectious Diseases

Related: Cohort Study: Incidence rates and clinical outcomes of SARS-CoV-2 infection with the Omicron and Delta variants in children younger than 5 years in the US.

 

Commentary on Twitter

 

Clinical update on COVID-19 for the emergency and critical care clinician: Medical management.

11 Apr, 2022 | 02:00h | UTC

Clinical update on COVID-19 for the emergency and critical care clinician: Medical management – American Journal of Emergency Medicine

 

Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.

11 Apr, 2022 | 01:58h | UTC

Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis – The Lancet

Invited Commentary: How to interpret the total number of SARS-CoV-2 infections – The Lancet

 

Commentary on Twitter (thread – click for more)

 

Review: Gastrointestinal post-acute COVID-19 syndrome.

11 Apr, 2022 | 01:49h | UTC

Gastrointestinal post-acute COVID-19 syndrome – Nature Reviews Gastroenterology & Hepatology

 

Commentary on Twitter

 

CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study.

11 Apr, 2022 | 01:40h | UTC

CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study – BMC Medicine

 

Clinical care of severe acute respiratory infections – Tool kit (COVID-19 adaptation, update 2022).

11 Apr, 2022 | 01:45h | UTC

Clinical care of severe acute respiratory infections – Tool kit – World Health Organization

 

Commentary on Twitter (thread – click for more)

 

Opinion | Why the WHO took two years to say COVID is airborne.

8 Apr, 2022 | 10:38h | UTC

Why the WHO took two years to say COVID is airborne – Nature

 

M-A: Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia.

8 Apr, 2022 | 10:50h | UTC

Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A Systematic Review and Meta-Analysis – International Journal of Infectious Diseases

Related:

Case series of Thrombosis with Thrombocytopenia Syndrome after Covid-19 vaccination in the US.

Review: Vaccine-induced immune thrombotic thrombocytopenia.

Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance.

Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)

 

Long COVID in children: a modified Delphi process.

8 Apr, 2022 | 10:40h | UTC

Long COVID (post-COVID-19 condition) in children: a modified Delphi process – Archives of Disease in Childhood

Related:

First research definition for ‘Long COVID’ in kids and young people formally agreed.

Cohort Study: Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England.

A nationwide cohort study in Denmark showed Long Covid in children is rare and mainly of short duration.

Editorial | Long covid in children and adolescents – “Risk appears low, but many questions remain”.

M-A: Persistent symptoms following SARS-CoV-2 infection among children and young people – “Higher study quality was associated with lower prevalence of all symptoms, except loss of smell and cognitive symptoms”.

Review: Long COVID symptoms in children rarely persist beyond three months.

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Do kids get long COVID? And how often? A pediatrician looks at the data – Children also get Long Covid, but much less often than adults.

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

 

M-A: Diagnostic performance of CO-RADS for Covid-19.

8 Apr, 2022 | 10:31h | UTC

Diagnostic performance of CO-RADS for COVID-19: a systematic review and meta-analysis – European Radiology

Related: CO-RADS – A categorical CT assessment scheme for patients with suspected COVID-19: definition and evaluation – Radiology

 

Study finds increased risk of pulmonary embolism up to 110 days after COVID-19.

7 Apr, 2022 | 10:06h | UTC

Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study – The BMJ

News Release: Study finds increased risk of serious blood clots up to six months after COVID-19 – BMJ

Editorial: Thromboembolism and bleeding after covid-19

Commentary: Covid: Blood clot risk higher for six months after having virus – BBC

 

M-A: Fluvoxamine for outpatient management of COVID-19 to prevent hospitalization.

7 Apr, 2022 | 09:55h | UTC

Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis – JAMA Network Open

Commentary: Common Antidepressant Likely Cuts Risk Of Covid Hospitalization, Study Finds – Forbes

Related:

Short Review: Fluvoxamine for symptomatic outpatients with COVID-19.

Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.

Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

 

Commentary on Twitter

 

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines.

7 Apr, 2022 | 10:00h | UTC

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines –
European Centre for Disease Prevention and Control

Related:

Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Commentary on Twitter (thread – click for more)

 

Pragmatic RCT: In outpatients with Covid-19, the addition of pulse oximetry for monitoring did not improve outcomes compared to subjective assessments of dyspnea alone.

7 Apr, 2022 | 09:58h | UTC

Pulse Oximetry for Monitoring Patients with Covid-19 at Home — A Pragmatic, Randomized Trial – New England Journal of Medicine

 

Commentary on Twitter

 

Perspective | Studying severe long COVID to understand post-infectious disorders beyond COVID-19.

7 Apr, 2022 | 08:45h | UTC

Studying severe long COVID to understand post-infectious disorders beyond COVID-19 – Nature Medicine

Related:

Review: Post-acute COVID-19 syndrome.

ESCMID rapid guidelines for assessment and management of long COVID.

ERS statement on Long COVID-19 follow-up.

Proposed subtypes of long-Covid and their respective potential therapies.

EuGMS Guidance: Management of post-acute COVID-19 patients in geriatric rehabilitation.

Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID.

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play.

Review | Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus.

The pathogenesis and long-term consequences of Covid-19 cardiac injury: state-of-the-art review.

COVID-19 infections increase risk of heart conditions up to a year later, study finds.

 

Commentary from the author on Twitter (thread – click for more)

 

Perspective | An equitable roadmap for ending the COVID-19 pandemic.

7 Apr, 2022 | 08:48h | UTC

An equitable roadmap for ending the COVID-19 pandemic – Nature Medicine

 

Commentary on Twitter

 

Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.

6 Apr, 2022 | 10:59h | UTC

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel – New England Journal of Medicine

Commentary: Mixed Bag for Fourth Dose of Pfizer Vaccine vs Omicron— Real-world data show less infection and severity, but long-term benefit less clear – MedPage Today (free registration required)

Related:

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Commentary on Twitter

 

Retrospective cohort study: Waning COVID-19 vaccine effectiveness for Pfizer and CoronaVac in Malaysia.

6 Apr, 2022 | 10:57h | UTC

Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study – International Journal of Infectious Diseases

 

Commentary on Twitter

 

Cohort Study: Incidence rates and clinical outcomes of SARS-CoV-2 infection with the Omicron and Delta variants in children younger than 5 years in the US.

6 Apr, 2022 | 10:52h | UTC

Incidence Rates and Clinical Outcomes of SARS-CoV-2 Infection With the Omicron and Delta Variants in Children Younger Than 5 Years in the US – JAMA Pediatrics

Commentary: Omicron ‘less severe’ than Delta for children ages 4 and younger, study suggests – Case Western Reserve University

 

Commentary on Twitter

 

Review and M-A: pulmonary rehabilitation for Post-Covid.

6 Apr, 2022 | 10:42h | UTC

Study 1: The effectiveness of pulmonary rehabilitation for Post-COVID symptoms: A rapid review of the literature – Respiratory Medicine

Study 2: Effect of Pulmonary Rehabilitation for Patients With Post-COVID-19: A Systematic Review and Meta-Analysis – Frontiers in Medicine

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.